目的：采用光学相干断层扫描(OCT)观察康柏西普治疗湿性年龄相关性黄斑变性(wARMD)后黄斑区视网膜结构的变化。

方法：选取2018-05/10本院收治的wARMD患者21例23眼为研究对象，均进行连续3mo、每月1次玻璃体内注射康柏西普治疗。末次注射后随访6mo，观察最佳矫正视力(BCVA)和眼压的变化，并采用OCT检查观察黄斑中心凹视网膜厚度(CFT)、黄斑中心凹旁视网膜厚度(PMT)和脉络膜新生血管(CNV)面积。

结果：治疗后6mo，本组患者治疗有效21眼(91%)，稳定2眼(9%)。治疗后1、3、6mo，本组患者BCVA较治疗前明显改善，CFT、PMT和CNV面积较治疗前明显下降(均P<0.05)，而眼压无明显变化(P>0.05)。随访期间仅2眼(9%)出现短暂视物模糊、1眼(4%)眼压升高(>21mmHg)、1眼(4%)球结膜下出血，均于末次注射康柏西普后7d内恢复。

结论：康柏西普治疗wARMD能显著改善视力及黄斑区视网膜结构，治疗效果佳，且副作用少，安全性高。

METHODS: From May 2018 to October 2018, 21 patients(23 eyes)with wARMD were studied. All patients were treated by intravitreal injection of conbercept monthly for 3mo. During the six-month follow-up period after the last injection, the changes of best corrected visual acuity(BCVA)and intraocular pressure were observed, in the meantime, the macular fovea retinal thickness(CFT), macular fovea pararetinal thickness(PMT), choroidal neovascularization(CNV)area and subretinal fibrosis also were observed by OCT.

RESULTS:Six months after treatment, 21 eyes(91%)was effective, and 2 eyes(9%)was stable in all patients. 1mo, 3mo and 6mo after treatment, the BCVA of patients were significantly improved, the areas of CFT, PMT and CNV decreased significantly compared with those of before(P<0.05), while intraocular pressure did not change significantly before and after treatment(P>0.05). During the follow-up period, transient blurred vision occurred in 2 eyes(9%), intraocular pressure increased(>21mmHg)in 1 eye(4%)and subconjunctival hemorrhage in 1 eye(4%)of 23 eyes, and all recovered within 7d after the end of 3 conbercept treatments.

CONCLUSION: The application of conbercept in the treatment of wARMD can significantly improve the patients' vision and retinal structure in macular region. And it also shows good therapeutic effect, less side effects and high safety.